找到相關結果： 944

Blocklisting Six Monthly Return

London: Friday, December 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: H

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-12-15

和黃醫藥在美國啟動呋喹替尼臨床試驗

1 個附件

2017年12 月15日：和黃醫藥今日宣佈在美國啟動呋喹替尼I期橋接臨床試驗。呋喹替尼是一種高選擇性強效口服血管內皮生長因子受體（VEGFR）1,2及3的抑製劑。呋喹替尼在中國以結直腸癌、肺�

下載新聞稿 (PDF)

公告及新聞稿, 監管通知 | 2017-11-01

TR-1: Notification of major interest in shares

公告及新聞稿, 監管通知 | 2017-11-01

TR-1: Notification of major interest in shares

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-10-31

和黃醫藥啟動呋喹替尼以二線胃癌為適應症的III期臨床研究FRUTIGA

1 個附件

2017年10月31日：和黃醫藥今日宣佈在中國啟動呋喹替尼聯合紫杉醇（泰素® ）以晚期胃癌或胃食管結合部（GEJ）腺癌為適應症的關鍵性III期臨床研究，這項研究被命名為FRUTIGA 。呋喹替尼是�

下載新聞稿 (PDF)

公告及新聞稿, 集團 | 2017-10-30

Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market

London: Monday, October 30, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the closing of its underwritten public offering of American Depositary Shares ("ADSs") on the Nasdaq Global Select Market, previously

公告及新聞稿, 集團 | 2017-10-27

Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Friday, October 27, 2017: Hutchison China MediTech L

公告及新聞稿, 集團 | 2017-10-26

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market (RNS)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Wednesday, October 25, 2017: Hutchison China MediTec

新聞稿, 集團 | 2017-10-26

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market

London: Wednesday, October 25, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the pricing of the underwritten public offering previously announced by Chi-Med on October 24, 2017. Chi-Med will issue and sell 9

公告及新聞稿, 集團 | 2017-10-25

Chi-Med Announces Proposed Offering of ADSs (RNS)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Tuesday, October 24, 2017: Hutchison China MediTech

新聞稿, 集團 | 2017-10-24

Chi-Med Announces Proposed Offering of ADSs

London: Tuesday, October 24, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that it intends to offer, subject to market and other conditions, US$262.0 million of American Depositary Shares (“ADSs”), each

公告及新聞稿, 監管通知 | 2017-10-19

TR-1: Notification of major interest in shares

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-10-17

和黃醫藥聯合阿斯利康開發的沃利替尼二線治療MET擴增的EGFR突變肺癌患者展現出良好的臨床抗腫瘤活性

1 個附件

– 沃利替尼聯合泰瑞莎® 或易瑞沙® 的臨床研究數據於世界肺癌大會公佈– –新公佈的數據有助於理解MET 擴增的EGFR突變NSCLC的疾病進展過程和探索潛在的新一代治療策略–

下載新聞稿 (PDF)

演示文稿, 科學出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Iressa® in MET-driven NSCLC

OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han

演示文稿, 科學出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC

OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-10-16

和黃醫藥公佈呋喹替尼聯合療法用於肺癌一線治療的II期臨床研究初步結果

1 個附件

– 呋喹替尼聯合易瑞沙® （吉非替尼）展現出良好的療效和安全性– – 進一步證實呋喹替尼因其高選擇性和出眾的安全性而具有與其他癌症療法相聯合的巨大潛力– 2017年10

下載新聞稿 (PDF)

演示文稿, 科學出版物 | 2017-10-15

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC

JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su Venue: IA

公告及新聞稿, 新聞稿, 集團 | 2017-10-12

和黃醫藥董事會董事任命

1 個附件

2017 年10 月12 日：和黃中國醫藥科技有限公司（簡稱“ 和黃醫藥 ”或“Chi-Med”）（納斯達克/倫敦證交所：HCM）今日宣布任命莫樹錦（Tony Mok ）教授擔任公司獨立非執行董事，同時擔任

下載新聞稿 (PDF)

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-09-29

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

Press Release – Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib – – Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgroups

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-09-29

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

Press Release – Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa® and Tagrisso® refractory patients with MET amplification – – Results to further validate Chi-Med’s scientific strategy of designing highly

公告及新聞稿, 監管通知 | 2017-09-29

Total Voting Rights

London: Friday, September 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 29, 2017, the issued share capital of Chi-Med consisted of 60,750,132 ord

演示文稿, 科學出版物 | 2017-09-28

CSCO 2017: Savolitinib Phase Ib in c-MET Gastric Cancer

Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,

演示文稿, 科學出版物 | 2017-09-28

CSCO 2017: Theliatinib Phase I Results

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong Venue: Chinese Society of Clinical Oncology Annual Meeting Session: Esophageal Cancer Presenter: Jif

演示文稿, 科學出版物 | 2017-09-27

CSCO 2017: FRESCO In-Depth Analysis

In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen

演示文稿, 科學出版物 | 2017-09-27

CSCO 2017: Theliatinib Preclinical Study in Esophageal Cancer

Is EGFR a “feasible” target for advanced esophageal cancer treatment? Rongxin Ren, Shiming Fan, Linfang Wang,Min Cheng, Dongxia Shi, Wei Zhang,Renxiang Tang, Ying Yu, Longxian Jiao, Jun Ni, Haibin Yang, Huaqing Cai,Feng Zhou, Weihan Zhang, Wei

公告及新聞稿, 監管通知 | 2017-08-31

Director's Share Dealing

London: Thursday, August 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated with Mr To,

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-08-29

和黃醫藥在中國啟動高選擇性PI3Kδ抑製劑HMPL-689以淋巴瘤為適應症的I期臨床試驗

1 個附件

2017年8月29日：和黃醫藥今日宣佈在中國啟動HMPL-689的I期臨床試驗。HMPL-689是一種新型高選擇性強效小分子抑製劑，靶向B 細胞受體信號通路中的關鍵蛋白磷酸肌醇-3激酶δ異構體（PI3Kδ）。 �

下載新聞稿 (PDF)

公告及新聞稿, 監管通知 | 2017-08-22

Director's Share Dealing

London: Tuesday, August 22, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 4,000 American Depositary Shares of

公告及新聞稿, 監管通知 | 2017-08-18

Directors' Share Dealing

London: Friday, August 18, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Wencheng Capital Limited (“WCL”), a person closely

公告及新聞稿, 監管通知 | 2017-08-15

Directors' Share Dealing

London: Tuesday, August 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (�

公告及新聞稿, 監管通知 | 2017-08-10

Director’s Share Dealing

London: Thursday, August 10, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 1,807 American Depositary Shares of th

公告及新聞稿, 監管通知 | 2017-08-07

Directors' Share Dealing

London: Monday, August 7, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (“P

公告及新聞稿, 集團 | 2017-07-31

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs

London: Monday, July 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the glob

公告及新聞稿, 監管通知 | 2017-06-30

Total Voting Rights

London: Friday, June 30, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 30, 2017, the issued share capital of Chi-Med consisted of 60,737,204 ordinary shar

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-29

和黃醫藥與阿斯利康聯手啟動沃利替尼治療乳頭狀腎細胞癌的全球III期臨床試驗“SAVOIR”

1 個附件

阿斯利康製藥（“阿斯利康”） (LON/STO/NYSE: AZN) 和黃中國醫藥科技有限公司（簡稱 “和黃醫藥”）（納斯達克/倫敦證交所：HCM） 2017 年6 月29 日：和黃醫藥今日宣布

下載新聞稿 (PDF)

公告及新聞稿, 監管通知 | 2017-06-29

Blocklisting Six Monthly Return

London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of sc

公告及新聞稿, 新聞稿, 集團 | 2017-06-29

Chi-Med to Announce 2017 Half-Year Financial Results

London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2017 on Monday, July 31, 2017 at 7:00 am British Summer Time (BST). An ana

演示文稿, 科學出版物 | 2017-06-23

Journal of Clinical Oncology: Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced PRCC

Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal Abstract Pur

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-22

和黃醫藥在中國啟動新型FGFR抑製劑HMPL 453的I/II期臨床試驗

1 個附件

2017年6月22日：和黃醫藥近日在中國啟動HMPL-453的I/II期臨床試驗。HMPL-453是一種靶向成纖維細胞生長因子受體（FGFR）的新型高選擇性小分子抑製劑。2017年6月19日首位受試者接受給藥治療。該�

下載新聞稿 (PDF)

公告及新聞稿, 監管通知 | 2017-06-16

Director’s Share Dealing

London: Friday, June 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Dynamic Drive Limited, a person closely associated (“PCA”) with Mr Simon To, Executive Director and Chairma

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-12

和黃醫藥向國家食品藥品監督管理局遞交呋喹替尼治療晚期結直腸癌的新藥上市申請

1 個附件

– 國家食品藥品監督管理局已受理申請，並將由藥品審評中心作技術審核– –將收到來自禮來共計3080萬人民幣的里程碑付款– 2017年6月12日：和黃醫藥今日宣布藥物呋喹替�

下載新聞稿 (PDF)

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-06-05

和黃醫藥在ASCO年會上就呋喹替尼臨床III期研究數據進行口頭報告

1 個附件

2017年6月5日：和黃醫藥宣佈在今天於美國芝加哥舉行的美國臨床腫瘤學會（ASCO）年會上就其自主研發的高選擇性血管細胞內皮生長因子受體（VEGFR）抑製劑的關鍵III期臨床研究結果進行了口�

下載新聞稿 (PDF)

演示文稿, 科學出版物 | 2017-06-05

ASCO 2017: Fruquintinib Phase III in Metastatic Colorectal Cancer (FRESCO)

A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO) Venue: American Society of Clinical Oncol

演示文稿, 科學出版物 | 2017-06-05

ASCO 2017: Sulfatinib Phase II in Medullary and Differentiated Thyroid Cancer

A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) Venue: American Society of Clinical Oncology Annual Meeti

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-05-18

和黃醫藥在ASCO 2017年會上公佈臨床數據

1 個附件

–受ASCO組委會邀請口頭報告呋喹替尼治療結直腸癌的III 期臨床研究“ FRESCO”的研究結果– –將在大會上展示呋喹替尼，沃利替尼和索凡替尼共5項研究摘要– 2017年5

下載新聞稿 (PDF)

公告及新聞稿, 監管通知 | 2017-04-28

Total Voting Rights

London: Friday, April 28, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 28, 2017, the issued share capital of Chi-Med consisted of 60,735,104 ordinary sh

公告及新聞稿, 監管通知 | 2017-04-27

Results of Annual General Meeting

London: Thursday, April 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2017 were duly

公告及新聞稿, 新聞稿, 腫瘤學 / 免疫學 | 2017-04-07

和黃醫藥在2017年AACR年會上公佈呋喹替尼和索凡替尼的臨床前數據

1 個附件

2017 年4 月7 日：和黃醫藥在2017 年4 月1 日至5 日於美國華盛頓舉行的美國癌症研究協會(AACR) 年會上公佈了呋喹替尼和索凡替尼的臨床前數據。呋喹替尼和索凡替尼目前都在以多種癌症�

下載新聞稿 (PDF)

演示文稿, 科學出版物 | 2017-04-04

AACR 2017: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases

Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases Authors: Jinghong Zhou, Jun Ni, Min Cheng, Na Yang, Junqing Liang, Liang Ge, Wei Zhang, Jianxing Tang, Qiaoling Sun, Fu Li, Jia Hu,

演示文稿, 科學出版物 | 2017-04-03

AACR 2017: Fruquintinib combinations with targeted therapies or immune checkpoint inhibitors in preclinical tumor models

Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models Authors: Yongxin Ren, Qiaoling Sun, Jingwen Long, Shiming Fan, Renxiang Tang,

1 2 3 4 5 6 7 8 9 10 11

13 14 15 16 17 18 19